Pharmacoeconomic Guidelines: Colombia

Country/Region: Colombia
PE Guidelines
PE Guidelines Source:
Instituto de Evaluación Tecnológica en Salud (IETS) (Institute of Health Technology Assessment)
Additional Information:

IETS Methods on the Participatory Process (IETS 2014)

Technical Documents for the construction of the Reference Case for Health Economic Evaluation in Colombia (IETS 2014) (in English)

Information current as of Tuesday, July 19, 2022

Key Features

Type of Guidelines PE Guidelines
Title and year of the document Manual para la elaboración de evaluaciones económicas en salud (2014) Guidelines for the Development of Health Economic Evaluations
Affiliation of authors Instituto de Evaluación Tecnológica en Salud (IETS) Institute of Health Technology Assessment (IETS)
Purpose of the document The purpose of these guidelines is to provide guidance on the methods for the economic evaluation of health care technologies in Colombia, especially as it relates to informing coverage and financing decisions for the Colombian Obligatory Health Care Plan. It describes key principles, preferred data sources and reporting recommendations for all organizations developing an economic evaluation in Colombia. It aims to reduce variability in methods and data sources to enhance reproducibility and transparency.
Standard reporting format included Yes (included on page 8-9).
Disclosure Yes.
Target audience of funding/ author's interests Decision makers, researchers, universities, pharmaceutical industry.
Perspective The health care system perspective.
Indication Only indications approved in Colombia by the relevant authority, the National Institute of Drug and Food Monitoring (INVIMA).
Target population It must be clearly stated, as well as outcomes related to each relevant subgroup, if necessary. It must also be discussed with relevant stakeholders, such as methodological and clinical experts, patients and caregivers, health professionals, relevant scientific associations and others, as indicated in the "IETS Methods on the Participatory Process".
Subgroup analysis Yes
Choice of comparator All relevant comparators must be identified as used in common practice in Colombia. The comparators must be discussed with and justified by relevant stakeholders, such as clinical experts as well as regulatory authorities.
Time horizon It must be sufficiently long to reflect all important differences in costs or outcomes between the technologies being compared (more details available on p.15).
Assumptions required Yes. They must be clearly reported and explained.
Preferred analytical technique Cost-Utility Analysis, (CUA).
Costs to be included Direct costs for the health care system should be considered. Indirect costs and direct non-medical costs should be excluded, such as productivity and other costs assumed by patients on the base case (more details available on p.15).
Source of costs Official databases and Colombian tariff manuals. If necessary, cost information can be requested from insurers and providers (more details available on p.21-23).
Modeling Yes. All assumptions must be clearly stated and discussed with relevant stakeholders (more details available on p. 24).
Systematic review of evidences Yes. The source for each parameter of the model must be clearly stated.
Preference for effectiveness over efficacy Yes.
Preferred outcome measure QALY.
Preferred method to derive utility EQ-5D using tariffs from a Latin American sample of the USA valuation study.
Equity issues stated The QALY has the same weight.
Discounting costs Base: 5%; SA: 0 - 12%
Discounting outcomes Base: 5%; SA: 0 - 12%
Sensitivity analysis-parameters and range One-way sensitivity analysis for the effectiveness and unit cost of the intervention, utility weights and discount rate. Probabilistic sensitivity analysis to assess overall uncertainty. Cost-effectiveness acceptability curves and scatterplot to present results.
Sensitivity analysis-methods Deterministic Sensitivity Analysis and Probabilistic Sensitivity Analysis.
Presenting results Yes. Using standard reporting format is recommended (as presented on p.27).
Incremental analysis Yes.
Total costs vs effectiveness (cost/effectiveness ratio) No.
Portability of results (Generalizability) No.
Financial impact analysis It is not required for the base case analysis. If a budget impact analysis is required, there are separate guidelines, available at
Mandatory or recommended or voluntary Recommended.


Aurelio Mejía, MSc, Deputy Director of Health Technology Assessment, Institute of Health Technology Assessment, Bogota, Colombia and Mabel Moreno, MS, Senior Economist, Institute of Health Technology Assessment, Bogota, Colombia contributed to the key feature form.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on Update my browser now